Reducing kidney damage caused by cisplatin cancer treatment
Official title: Inhibition of diacylglycerol lipase α as a novel strategy to mitigate the nephrotoxicity of cisplatin
Funded at Virginia Commonwealth University · NIH-11034266 · Data updated 2026-11-12
This study is looking at a new way to help protect your kidneys from damage while using cisplatin, a common chemotherapy drug for cancer, by exploring how certain natural compounds can make the treatment safer and more effective for you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $227,221 |
| NIH project number | 1R21CA289216-01A1 |
| Project ID | NIH-11034266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are scheduled to receive cisplatin as part of their treatment regimen.
✕Less likely to help
Patients who are not receiving cisplatin or those with pre-existing severe kidney conditions may not benefit from this research.
What this research studies
This research investigates a new approach to protect the kidneys from damage caused by cisplatin, a common chemotherapy drug used to treat various cancers. The study focuses on the endocannabinoid system, particularly how certain compounds can mitigate nephrotoxicity associated with cisplatin treatment. By exploring the role of diacylglycerol lipase α in kidney health, the research aims to develop strategies that could enhance the safety and effectiveness of cisplatin therapy for cancer patients. Patients may be monitored for kidney function and overall health during the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney protection for cancer patients undergoing cisplatin treatment, potentially allowing for higher doses and better treatment outcomes.
How similar studies have gone: Previous research has shown promise in using endocannabinoid system interventions to address kidney damage, suggesting that this approach may be effective.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Li, Ningjun — Virginia Commonwealth University
- Study coordinator: Li, Ningjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.